An update of new targets for cancer treatment: vessels and matrix.
Bicknell
R
R
Molecular Angiogenesis Laboratory, Cancer Research UK, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D001808:Blood Vessels / Q000187:drug effects* / Q000254:growth & development; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D011322:Primary Prevention / Q000379:methods; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors